Boehringer Ingelheim 보도자료

2022년 10월 21일 10:40

베링거인겔하임-튀빙겐 대학교, AI·데이터과학 연구 개발로 의학 발전 이끌 펠로십 프로그램 발족

유럽 최대 인공지능(AI) 연구 컨소시엄 사이버밸리(Cyber Valley)의 회원인 튀빙겐 대학교(University of Tübingen, 이하 튀빙겐)와 베링거인겔하임(Boehringer Ingelheim)이 전 세계 우수 인재들을 위한 AI·데이터과학 펠로십 프로그램을 선보인다. 먼저 최대 3년 ...

2022년 10월 17일 11:35

CHMP recommends conditional marketing authorization for Spesolimab as first in class treatment option for generalized pustular psoriasis flares

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional market authorization[*] for Boehringer Ingelheim’s spesolimab as first in class treatment option for generalized pustula...

2022년 10월 5일 17:15

Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements

Boehringer Ingelheim announced today that Cowtribe is the first recipient of investment and non-financial support from the Boehringer Ingelheim Social Engagement (BI SE) initiative, a program which aims to close a critical financing gap for social...

2022년 9월 6일 10:30

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosin...

2022년 9월 2일 16:55

U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults

The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults, Boehringer Ingelheim announced today. Spesolimab, marketed in the U.S. a...

2022년 8월 4일 15:45

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political ...

2022년 7월 6일 16:15

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, ann...

2022년 6월 15일 09:50

Boehringer Ingelheim signs Option to Acquire Trutino Biosciences

Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company. Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and de...

2022년 6월 3일 11:30

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products ...

2022년 5월 16일 09:30

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was published in The New England Journal of Medicine (NEJM). The promising 12-week data that showed a reductio...

2022년 4월 21일 17:20

Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses

It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team. That’s why a tendon or ligament injury can be devastating for horse owners, riders and trainers. For equine ath...

2022년 4월 5일 17:30

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

In 2021, Boehringer Ingelheim again stepped up its annual investments in R&D to a new high in its 137-year history. The company spent 4.1 billion EUR on R&D (2020: 3.7 billion EUR), up 11.7%. R&D investments in Human Pharma rose to 3.7 billion EUR...

2022년 3월 17일 10:15

Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

The EMPA-KIDNEY trial, evaluating the effect of empagliflozin in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee. This follows a formal interim assessment t...

2022년 3월 7일 16:40

Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction

The European Commission (EC) has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company have announced.[1] The landmark approv...

2022년 2월 2일 12:00

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer ...

2022년 1월 20일 17:05

Award: Boehringer Ingelheim is Global Top Employer 2022

The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best employers. The award shows that the research-driven pharmaceutical company is strongly oriented to t...

2021년 12월 23일 16:30

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 trial, which showed spesolimab, a first-in-class investigational treatment, significantly improved sign...

2021년 11월 8일 15:30

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

Empagliflozin reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40 p...

2021년 10월 29일 17:00

Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis

Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agenc...

2021년 10월 28일 11:45

Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in peopl...

2021년 10월 27일 09:40

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Boehringer Ingelheim and Thoeris GmbH announce a collaboration and license agreement with the aim to investigate novel first-in-class therapies for patients with urea cycle disorders (UCDs). UCDs are rare diseases caused by genetic liver dysfuncti...

2021년 10월 19일 17:55

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh) and Oxford Biomedica (OXB), announced today that Boehringer I...

2021년 9월 23일 16:10

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed ...

2021년 9월 17일 13:35

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1::pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMA...

2021년 9월 10일 15:30

Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly a...

Boehringer Ingelheim

Boehringer Ingelheim 보도자료

회사 보도자료 구독